Verapamil inhibition of the intestinal effects of substance P

M. J. Zinner, D. Sherlock, A. Ferrara, D. McFadden, R. B. Wait, B. M. Jaffe

Research output: Contribution to journalArticle

Abstract

The undecapeptide substance P (SP) is contained in enterochromaffin cells and circulates in high concentrations in patients with carcinoid syndrome. We have previously reported that elevated SP levels, simulating those reported in patients with carcinoid syndrome, induce profound changes in intestinal water and electrolyte secretion, motility, and blood flow in a canine model. The purpose of this study was to attempt to block the effects of circulating carcinoid levels of SP on intestinal secretion and motility with the calcium channel blocker verapamil. In five dogs a chronic proximal jejunal Thiry-Vella loop was constructed, and after a 2-week recovery the loops were perfused with an isotonic test solution containing 14C-polyethylene glycol as a volume marker. Motor activity was measured by changes in intraluminal pressure and a motility index was calculated with computer-assisted planimetry and expressed as square millimeters per 5 minutes. After a 30-minute baseline period, SP was infused at 50 ng/kg/min for 90 minutes. SP circulating levels rose from a baseline of 6.2 ± 1.3 pg/ml to a peak of 93.3 ± 3.1 pg/ml during this infusion. Thirty minutes after the start of this SP infusion, a simultaneous infusion of verapamil (5.0 μg/kg/min) was begun at a separate site. During SP infusion there was a significant secretory response of water (-48 ± 12 μl/min), Na+ (-7.7 ± 2.5 μEq/min), Cl- (-8.8 ± 2.7 μEq/min) and K+ (-0.57 ± 0.14 μEq/min), and hypermotility (motility index: 1479 ± 138 mm2/5 min). When verapamil was added a reversal of secretion to net absorption was observed (water: +116.9 ± 15.6 μl/min; Na+: +13.8 ± 2.1 μEq/min; Cl-: +5.5 ± 2 μEq/min; K+: +0.38 ± 0.9 μEq/min) (p <0.05). In addition, there was a reduction in motility (motility index: 853 ± 92 mm2/5 min; p <0.05). These results confirm that SP has profound effects on both intestinal motility and secretion and that calcium channel blockade reduces these effects significantly.

Original languageEnglish (US)
Pages (from-to)230-235
Number of pages6
JournalSurgery
Volume98
Issue number2
StatePublished - 1985
Externally publishedYes

Fingerprint

Substance P
Verapamil
Carcinoid Tumor
Intestinal Secretions
Gastrointestinal Motility
Water
Enterochromaffin Cells
Isotonic Solutions
Inhibition (Psychology)
Calcium Channel Blockers
Calcium Channels
Electrolytes
Canidae
Motor Activity
Dogs
Pressure

ASJC Scopus subject areas

  • Surgery

Cite this

Zinner, M. J., Sherlock, D., Ferrara, A., McFadden, D., Wait, R. B., & Jaffe, B. M. (1985). Verapamil inhibition of the intestinal effects of substance P. Surgery, 98(2), 230-235.

Verapamil inhibition of the intestinal effects of substance P. / Zinner, M. J.; Sherlock, D.; Ferrara, A.; McFadden, D.; Wait, R. B.; Jaffe, B. M.

In: Surgery, Vol. 98, No. 2, 1985, p. 230-235.

Research output: Contribution to journalArticle

Zinner, MJ, Sherlock, D, Ferrara, A, McFadden, D, Wait, RB & Jaffe, BM 1985, 'Verapamil inhibition of the intestinal effects of substance P', Surgery, vol. 98, no. 2, pp. 230-235.
Zinner MJ, Sherlock D, Ferrara A, McFadden D, Wait RB, Jaffe BM. Verapamil inhibition of the intestinal effects of substance P. Surgery. 1985;98(2):230-235.
Zinner, M. J. ; Sherlock, D. ; Ferrara, A. ; McFadden, D. ; Wait, R. B. ; Jaffe, B. M. / Verapamil inhibition of the intestinal effects of substance P. In: Surgery. 1985 ; Vol. 98, No. 2. pp. 230-235.
@article{67b2d380f4d844bab8b44ff69590c30e,
title = "Verapamil inhibition of the intestinal effects of substance P",
abstract = "The undecapeptide substance P (SP) is contained in enterochromaffin cells and circulates in high concentrations in patients with carcinoid syndrome. We have previously reported that elevated SP levels, simulating those reported in patients with carcinoid syndrome, induce profound changes in intestinal water and electrolyte secretion, motility, and blood flow in a canine model. The purpose of this study was to attempt to block the effects of circulating carcinoid levels of SP on intestinal secretion and motility with the calcium channel blocker verapamil. In five dogs a chronic proximal jejunal Thiry-Vella loop was constructed, and after a 2-week recovery the loops were perfused with an isotonic test solution containing 14C-polyethylene glycol as a volume marker. Motor activity was measured by changes in intraluminal pressure and a motility index was calculated with computer-assisted planimetry and expressed as square millimeters per 5 minutes. After a 30-minute baseline period, SP was infused at 50 ng/kg/min for 90 minutes. SP circulating levels rose from a baseline of 6.2 ± 1.3 pg/ml to a peak of 93.3 ± 3.1 pg/ml during this infusion. Thirty minutes after the start of this SP infusion, a simultaneous infusion of verapamil (5.0 μg/kg/min) was begun at a separate site. During SP infusion there was a significant secretory response of water (-48 ± 12 μl/min), Na+ (-7.7 ± 2.5 μEq/min), Cl- (-8.8 ± 2.7 μEq/min) and K+ (-0.57 ± 0.14 μEq/min), and hypermotility (motility index: 1479 ± 138 mm2/5 min). When verapamil was added a reversal of secretion to net absorption was observed (water: +116.9 ± 15.6 μl/min; Na+: +13.8 ± 2.1 μEq/min; Cl-: +5.5 ± 2 μEq/min; K+: +0.38 ± 0.9 μEq/min) (p <0.05). In addition, there was a reduction in motility (motility index: 853 ± 92 mm2/5 min; p <0.05). These results confirm that SP has profound effects on both intestinal motility and secretion and that calcium channel blockade reduces these effects significantly.",
author = "Zinner, {M. J.} and D. Sherlock and A. Ferrara and D. McFadden and Wait, {R. B.} and Jaffe, {B. M.}",
year = "1985",
language = "English (US)",
volume = "98",
pages = "230--235",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Verapamil inhibition of the intestinal effects of substance P

AU - Zinner, M. J.

AU - Sherlock, D.

AU - Ferrara, A.

AU - McFadden, D.

AU - Wait, R. B.

AU - Jaffe, B. M.

PY - 1985

Y1 - 1985

N2 - The undecapeptide substance P (SP) is contained in enterochromaffin cells and circulates in high concentrations in patients with carcinoid syndrome. We have previously reported that elevated SP levels, simulating those reported in patients with carcinoid syndrome, induce profound changes in intestinal water and electrolyte secretion, motility, and blood flow in a canine model. The purpose of this study was to attempt to block the effects of circulating carcinoid levels of SP on intestinal secretion and motility with the calcium channel blocker verapamil. In five dogs a chronic proximal jejunal Thiry-Vella loop was constructed, and after a 2-week recovery the loops were perfused with an isotonic test solution containing 14C-polyethylene glycol as a volume marker. Motor activity was measured by changes in intraluminal pressure and a motility index was calculated with computer-assisted planimetry and expressed as square millimeters per 5 minutes. After a 30-minute baseline period, SP was infused at 50 ng/kg/min for 90 minutes. SP circulating levels rose from a baseline of 6.2 ± 1.3 pg/ml to a peak of 93.3 ± 3.1 pg/ml during this infusion. Thirty minutes after the start of this SP infusion, a simultaneous infusion of verapamil (5.0 μg/kg/min) was begun at a separate site. During SP infusion there was a significant secretory response of water (-48 ± 12 μl/min), Na+ (-7.7 ± 2.5 μEq/min), Cl- (-8.8 ± 2.7 μEq/min) and K+ (-0.57 ± 0.14 μEq/min), and hypermotility (motility index: 1479 ± 138 mm2/5 min). When verapamil was added a reversal of secretion to net absorption was observed (water: +116.9 ± 15.6 μl/min; Na+: +13.8 ± 2.1 μEq/min; Cl-: +5.5 ± 2 μEq/min; K+: +0.38 ± 0.9 μEq/min) (p <0.05). In addition, there was a reduction in motility (motility index: 853 ± 92 mm2/5 min; p <0.05). These results confirm that SP has profound effects on both intestinal motility and secretion and that calcium channel blockade reduces these effects significantly.

AB - The undecapeptide substance P (SP) is contained in enterochromaffin cells and circulates in high concentrations in patients with carcinoid syndrome. We have previously reported that elevated SP levels, simulating those reported in patients with carcinoid syndrome, induce profound changes in intestinal water and electrolyte secretion, motility, and blood flow in a canine model. The purpose of this study was to attempt to block the effects of circulating carcinoid levels of SP on intestinal secretion and motility with the calcium channel blocker verapamil. In five dogs a chronic proximal jejunal Thiry-Vella loop was constructed, and after a 2-week recovery the loops were perfused with an isotonic test solution containing 14C-polyethylene glycol as a volume marker. Motor activity was measured by changes in intraluminal pressure and a motility index was calculated with computer-assisted planimetry and expressed as square millimeters per 5 minutes. After a 30-minute baseline period, SP was infused at 50 ng/kg/min for 90 minutes. SP circulating levels rose from a baseline of 6.2 ± 1.3 pg/ml to a peak of 93.3 ± 3.1 pg/ml during this infusion. Thirty minutes after the start of this SP infusion, a simultaneous infusion of verapamil (5.0 μg/kg/min) was begun at a separate site. During SP infusion there was a significant secretory response of water (-48 ± 12 μl/min), Na+ (-7.7 ± 2.5 μEq/min), Cl- (-8.8 ± 2.7 μEq/min) and K+ (-0.57 ± 0.14 μEq/min), and hypermotility (motility index: 1479 ± 138 mm2/5 min). When verapamil was added a reversal of secretion to net absorption was observed (water: +116.9 ± 15.6 μl/min; Na+: +13.8 ± 2.1 μEq/min; Cl-: +5.5 ± 2 μEq/min; K+: +0.38 ± 0.9 μEq/min) (p <0.05). In addition, there was a reduction in motility (motility index: 853 ± 92 mm2/5 min; p <0.05). These results confirm that SP has profound effects on both intestinal motility and secretion and that calcium channel blockade reduces these effects significantly.

UR - http://www.scopus.com/inward/record.url?scp=0022322988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022322988&partnerID=8YFLogxK

M3 - Article

C2 - 2410986

AN - SCOPUS:0022322988

VL - 98

SP - 230

EP - 235

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 2

ER -